Navigation Links
Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
Date:4/25/2008

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

In a late-breaking abstract presented at the 1st European Lung Cancer Conference jointly organized by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), Prof. Giorgio Scagliotti from the University of Torino, Italy presented data from the clinical trial stopped in February.

For some patients, the drug results in worse outcomes. "Based on a planned interim analysis the study showed a clear inferiority from adding sorafenib to carboplatin/paclitaxel in first-line non-small-cell lung cancer patients with squamous histology," Prof. Scagliotti said.

Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.

The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.

After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.

"To date there is no evidence of any detrimental effect from sorafenib in additional subgroups of patients," Prof. Scagliotti said.

He noted that researchers are still studying the drug in lung cancer, including an ongoing study examining adding it to the combination of cisplatin and gemcitabine.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Invention gives improved gene technology analysis
2. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
3. Genome analysis reveals new protein associated with breast cancer progression
4. Analysis Highlights Economic Contribution of Hospitals to Communities
5. SAIC Awarded DIA Intelligence Analysis Contract
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. Some Cancer Trials Overstate Findings, Analysis Claims
10. Review of group-based cancer trials reveals flaws in studies design and analysis
11. Stanford University School of Medicine to Address Improving Network Security and Management at EDUCAUSE Western Regional Conference 2008 Using Lancopes StealthWatch System for Network Behavior Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... Every year 220 Mississippi kids are diagnosed ... children. The wishes provide hope and motivation through positive experiences while they ... Brent Wilson said, “In 2016, the organization will grant 50% of wishes deemed ...
(Date:5/5/2016)... , ... May 05, 2016 , ... A recent survey ... to face challenges in getting employees to understand and use the free preventive care ... the nation’s leading non-profit business groups of large, self-insured public and private employers, MBGH ...
(Date:5/5/2016)... ... May 05, 2016 , ... A local study ... more than 40 percent of participating fifth-grade students already have or are at ... Asthma Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered ... the organization’s successful Care Transitions program at the 9th Annual Orthopedic ... “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” , Major ...
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
Breaking Medicine Technology: